anticholinesterase drugs

anticholinesterase drugs 

Parasympathetic drugs that inhibit or inactivate the enzyme acetylcholinesterase, allowing prolonged activity of acetylcholine. They cause miosis and ciliary muscle contraction. There are two groups: reversible which are of short duration (up to 12 hours or so), such as neostigmine, physostigmine and edrophonium chloride, and irreversible which lasts for days or weeks, such as demecarium bromide and diisopropyl fluorophosphate (DFP). See acetylcholinesterase; miotics.
References in periodicals archive ?
After surgery, patients were transferred to the intensive care unit for elective overnight ventilation; midazolam and fentanyl infusions were discontinued early morning of the following day, no anticholinesterase drugs were added, and patients received their normal myasthenic therapy via the nasogastric tube.
These variants are more likely to affect the duration of response when present with other factors that influence BChE activity, such as a qualitative BChE variant, pregnancy, and anticholinesterase drugs (9).
Conventional treatment involves the use of steroid immune system suppressers such as prednisone, and anticholinesterase drugs, usually pyrodostigmine.
A nondepolarising neuromuscular blocking agent is an alternative, however their disadvantages include long duration of action, less effectiveness for deep neuromuscular blocking and muscarinic side-effects of anticholinesterase drugs (3,4) when they are used for reversal.
Both trials included patients who had been stable on anticholinesterase drugs for at least 3 months prior to the study.
Nice is recommending that the anticholinesterase drugs ( Aricept, Exelon and Reminyl ( should only be available for people in the moderate stages of the disease.
They are recommending that the anticholinesterase drugs (Aricept, Exelon and Reminyl) should only be available for people in the moderate stages of Alzheimer's disease.
Restricting access to the anticholinesterase drugs to people with an MMSE score of between 10 and 20 will discourage early diagnosis and counteract the positive work in recent years to encourage people to seek help earlier.
These costs can be much lower if anticholinesterase drugs are received in the early stages of Alzheimer's.
The administration of these anticholinesterase drugs focused attention on the neuromuscular junction in myasthenia gravis patients.
We do know that treatment of the dementia with anticholinesterase drugs helps but we do not know if risk factor control will decrease the incidence and severity of vascular cognitive change.
With the availability of anticholinesterase drugs for treating Alzheimer's disease, PET diagnosis has an important role to play in determining patient management, said Dr.